证券日报网讯瑞康医药（002589）9月25日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东户数为73，032户。 ...

山东乾元律师事务所·法律意见书 关于瑞康医药集团股份有限公司 2025 年第一次临时股东会的律师见证法律意见书 致：瑞康医药集团股份有限公司 山东乾元律师事务所（以下简称"本所"）接受贵公司的委托，指派 时晓旸、衣超律师（以下简称"本所律师"）出席贵公司于 2025 年 9 月 22 日下午 15 点在位于山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室举行 的 2025 年第一次临时股东会（以下简称"本次股东会"），并根据《中华 人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 及《上市公司股东会规则》等法律法规及规范性文件和《瑞康医药集团股 份有限公司章程》（以下简称"《公司章程》"）的规定，就本次股东会 的召集与召开程序、出席会议人员的资格和召集人的资格、审议事项以及 表决方式、表决程序、表决结果依法进行见证，并出具法律意见。 为出具本法律意见书，本所律师审查了贵公司提供的以下文件，包括: 1、贵公司的《公司章程》； 2、贵公司于 2025 年 9 月 5 日召开的第五届董事会第十八次会议决议； 3、贵公司于 2025 年 9 月 6 日在《证券时报》、《中国证券报》、《证 券日 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-048 瑞康医药集团股份有限公司 2025 年第一次临时股东会决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述和重大遗漏。 一、 重要提示 1、本次股东会未涉及变更以往股东会已通过的决议。 2、本次股东会召开期间没有增加、否决或变更议案的情况发生。 二、 会议通知情况 《瑞康医药集团股份有限公司关于召开 2025 年第一次临时股东会的通知》 于 2025 年 9 月 6 日在《证券时报》、《中国证券报》、《证券日报》、《上海 证券报》和巨潮资讯网上已经披露。 三、 会议召开基本情况 1、会议召集人：公司董事会 2、会议时间：2025 年 9 月 22 日（星期一）下午 15:00 3、会议召开地点：山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室 4、会议主持人：董事长、总裁韩旭先生 5、会议召开方式：现场会议结合网络投票方式 6、本次会议的召集、召开符合《公司法》、《上市公司股东会规则》、《深 圳证券交易所股票上市规则》及《公司章程》等有关法律、法规及规范性文件的 规定。 四、 会议出席情况 ...

Market Overview - The pharmaceutical commercial sector increased by 0.19% on September 16, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Top Gainers - Saily Medical (603716) closed at 31.80, up 5.75% with a trading volume of 461,500 shares and a transaction value of 1.457 billion [1] - First Pharmaceutical (600833) closed at 14.33, up 3.47% with a trading volume of 159,400 shares and a transaction value of 229 million [1] - Ruikang Pharmaceutical (002589) closed at 3.05, up 2.35% with a trading volume of 564,800 shares and a transaction value of 170 million [1] Other Notable Stocks - Haiwang Biological (000078) closed at 2.72, up 1.87% with a trading volume of 472,600 shares and a transaction value of 128 million [1] - Yiyigou (300937) closed at 28.06, up 1.41% with a trading volume of 13,100 shares and a transaction value of 36.54 million [1] Market Capital Flow - The pharmaceutical commercial sector saw a net inflow of 1.0663 million from institutional investors, while retail investors had a net inflow of 3.2772 million [2] - However, speculative funds experienced a net outflow of 33.8383 million [2] Individual Stock Capital Flow - Saily Medical had a net inflow of 99.8444 million from institutional investors, while it faced a net outflow of 39.1679 million from speculative funds [3] - First Pharmaceutical saw a net inflow of 21.4721 million from institutional investors, but a net outflow of 2.02355 million from retail investors [3] - Ruikang Pharmaceutical had a net inflow of 8.2730 million from institutional investors, with a slight net outflow from speculative funds [3]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Ruikang Pharmaceutical, indicating a slight decline in stock price and specific financing activities [1][2] - As of September 9, Ruikang Pharmaceutical's stock price decreased by 0.68%, with a trading volume of 48.56 million yuan and a net financing purchase of 2.94 million yuan [1] - The company's financing balance is reported at 202 million yuan, which constitutes 4.59% of its market capitalization, indicating a low financing level compared to the past year [1] Group 2 - For the first half of 2025, Ruikang Pharmaceutical reported a revenue of 3.544 billion yuan, reflecting a year-on-year decrease of 12.11%, while the net profit attributable to shareholders was 18.17 million yuan, down 41.45% year-on-year [2] - The company has distributed a total of 393 million yuan in dividends since its A-share listing, with 36.03 million yuan distributed over the past three years [3]

Core Viewpoint - The major shareholder of Ruikang Pharmaceutical has completed a share reduction plan, which does not affect the company's control or governance structure [1]. Summary by Sections Shareholder Actions - The shareholder, Jiangzhou Zhaoshang Huize Pharmaceutical Investment Partnership, reduced its holdings by 100 shares at an average price of 3.00 yuan, representing a decrease of 0.0001% [1]. - After the reduction, the total shares held by Jiangzhou Zhaoshang Huize decreased from 75,235,525 shares to 75,235,425 shares, with the holding percentage dropping from 5.00% to 4.9999% [1]. Compliance and Impact - The company stated that the share reduction complies with relevant laws and regulations and was executed according to a previously disclosed plan, indicating no violations [1]. - Jiangzhou Zhaoshang Huize is not the controlling shareholder or actual controller of the company, and the reduction will not lead to any change in control or impact the company's governance structure and ongoing operations [1].

瑞康医药集团股份有限公司 关于持股5%以上股东股份减持计划实施完成的公告 瑞康医药集团股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日披露 了《关于持股 5%以上股东减持股份的预披露公告》（公告编号：2025-030）， 股东荆州招商慧泽医药投资合伙企业（有限合伙）（以下简称"招商慧泽"）计 划在该公告披露之日起 15 个交易日后的 3 个月内以集中竞价或大宗交易的方式 减持公司股份不超过 15,047,105 股（占公司总股本比例 1%）。 近日，公司收到招商慧泽出具的《关于股份减持计划期限届满的告知函》， 获悉上述股东的股份减持计划已实施完毕，现将相关情况公告如下： 一、股东减持情况 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持期间 | | 减持均价 | 减持数量 | 减持比例 | | --- | --- | --- | --- | --- | --- | --- | | 招商慧泽 | 集中竞价交 | 2025 年 | 5 月 | 3.00 | 100 | 0.0001 | | | 易 | 日 30 | | | | | 证券代码：002589 证券简称：瑞康医药 公告编号：2 ...

Core Viewpoint - Ruikang Pharmaceutical (002589) announced that as of the date of the announcement, the company has no overdue guarantees, no guarantee amounts involved in litigation, and no losses incurred due to being judged against in guarantee cases [1] Group 1 - The company has confirmed the absence of overdue guarantees [1] - There are no guarantee amounts related to any ongoing litigation [1] - The company has not incurred any losses from guarantees due to adverse judgments [1]

Core Points - The company held its 18th meeting of the 5th Board of Directors on September 5, 2025, with all 8 directors present, and the meeting was conducted in accordance with relevant laws and regulations [1] - The Board approved the revision of the company's articles of association to align with the latest legal requirements and the company's development strategy, with a unanimous vote of 8 in favor [1] - The Board also approved the revision of certain governance systems to enhance the company's governance structure, again with a unanimous vote of 8 in favor [2] - The company proposed a guarantee limit for itself and its subsidiaries totaling no more than RMB 2 billion, with specific limits based on the subsidiaries' asset-liability ratios, which was also approved unanimously [3] - A proposal to convene the 2025 first extraordinary general meeting was approved with a unanimous vote of 8 in favor [3]